Lake Street raised the firm’s price target on Castle Biosciences (CSTL) to $52 from $35 and keeps a Buy rating on the shares after the company announced preliminary 2025 revenue. As yesterday’s release was preliminary, the firm said it will update its model upon the release of final financial results, but it is are updating its price target to be based on 2026 revenue estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences expects FY25 revenue to exceed $340M
- Castle Biosciences price target raised to $43 from $30 at Guggenheim
- Castle Biosciences price target raised to $50 from $37 at Canaccord
- Castle Biosciences reports inducement grants under Nasdaq listing rule
- Castle Biosciences announces new data on DecisionDx-UM, PRAME